✉news BusinessLabor first seen 12 h ago, last 1 h ago, peak #9
Antibody-drug conjugates regain momentum in cancer treatment
Original: Vital Signs: ADCs strike back
Antibody-drug conjugates, a class of targeted cancer therapies, are reported to be striking back, suggesting renewed momentum for the technology after a period of setbacks. The item comes from FirstWord Pharma's Vital Signs series, which tracks notable developments in the pharmaceutical industry. Specific drugs, companies and clinical results behind the claim are not detailed.
Why now: ADC therapies are a major focus of oncology drug development and any sign of renewed success draws close industry attention.
FirstWord Pharmaantibody-drug conjugates
Rank over time, top of the chart is #1. 4 snapshots from 5 h ago to 1 h ago.
Evidence
- Vital Signs: ADCs strike back · FirstWord Pharma
API: https://socialmediatrends-api.osmike.com/v1/trends/1186291